ReviewFrontiers in chemistry2025
Surface-enhanced Raman spectroscopy for label-free cancer liquid biopsy: from fundamentals to clinical analysis of biofluid.
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Plasmonic Nanoarray Biosensors for Non-Invasive Cancer Diagnostics.Biosensors · 2026Review
- Biosensors for Circular RNA Profiling in Biological Matrices.Analytical chemistry · 2026Article
- Emerging Plasmonic Nanomaterials for SERS-Based Disease Diagnostics: Innovations, Clinical Challenges, and AI Integration.Molecules (Basel, Switzerland) · 2026Review
- AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.Biosensors · 2026Review
- Raman and surface-enhanced Raman spectroscopy for intraoperative cancer diagnostics: sentinel lymph node biopsy, biomarkers and translational challenges.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the major public health problems due to its high morbidity and mortality globally. Because metastasis is the major cause of cancer death, developing new approaches for early diagnosis is of paramount importance in this context. Surface-enhanced Raman scattering (SERS) has emerged as a cutting-edge analytical technique. SERS features an exceptional sensitivity and specificity, enabling rapid non-destructive detection of trace-level samples. Therefore, SERS technology is widely used across medical disciplines, particularly in cancer diagnosis for early-stage and non-invasive diagnostic evaluation. Using liquid biopsy with rich metabolic information, SERS has facilitated the identification, analysis, and progression monitoring of various cancers. In this review, we systematically summarize recent advances in label-free SERS-based cancer diagnostics. We first outline the fundamental principles of SERS, key substrate fabrication methodologies, and essential spectral analysis techniques. We then highlight the applications of label-free SERS in liquid biopsy using various biofluids, including blood, urine, saliva, and sweat. Finally, we discuss current challenges and future directions in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.